tiprankstipranks
Advertisement
Advertisement

SNY Stock Latest News

Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
The FlySanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
4d ago
SNY
Midday Fly By: Intel announces $15B offering, Meta unveils Muse Glimmer
PremiumThe Fly
Midday Fly By: Intel announces $15B offering, Meta unveils Muse Glimmer
5d ago
BA
ACH
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
PremiumThe Fly
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
5d ago
SNY
Sanofi Wins EU Approval to Use MenQuadfi in Infants From Six Weeks
PremiumCompany Announcements
Sanofi Wins EU Approval to Use MenQuadfi in Infants From Six Weeks
9d ago
6K
SNY
Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
PremiumCompany Announcements
Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
15d ago
SNY
REGN
Regeneron price target raised to $737 from $696 at RBC Capital
PremiumThe FlyRegeneron price target raised to $737 from $696 at RBC Capital
15d ago
SNY
REGN
Morning Movers: Baxter surges following beat and raise report
Premium
The Fly
Morning Movers: Baxter surges following beat and raise report
16d ago
MO
BAX
Sanofi expects FY26 sales to grow by around 10% at CER
Premium
The Fly
Sanofi expects FY26 sales to grow by around 10% at CER
16d ago
SNY
Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported
PremiumThe Fly
Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported
16d ago
SNY
Sanofi’s MenQuadfi Safety Study in Korea: What Investors Should Watch
PremiumCompany Announcements
Sanofi’s MenQuadfi Safety Study in Korea: What Investors Should Watch
17d ago
SNY
Sanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study
PremiumCompany Announcements
Sanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study
17d ago
SNY
Sanofi Pauses Key Bronchiectasis Trial, Raising Questions For SNY Investors
PremiumCompany Announcements
Sanofi Pauses Key Bronchiectasis Trial, Raising Questions For SNY Investors
17d ago
SNY
SNY Earnings this Week: How Will it Perform?
PremiumPre-EarningsSNY Earnings this Week: How Will it Perform?
18d ago
SNY
Sanofi Reshapes Executive Committee for Next Strategic Chapter
Premium
Company Announcements
Sanofi Reshapes Executive Committee for Next Strategic Chapter
19d ago
6K
SNY
Sanofi Advances Real-World Asthma Study, Sharpening Its Long-Term Biologics Strategy
Premium
Company Announcements
Sanofi Advances Real-World Asthma Study, Sharpening Its Long-Term Biologics Strategy
22d ago
SNY
Sanofi Targets New Growth With Bioequivalence Study for REZUROCK Suspension
PremiumCompany Announcements
Sanofi Targets New Growth With Bioequivalence Study for REZUROCK Suspension
22d ago
SNY
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
PremiumThe Fly
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
24d ago
XE
AAL
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
PremiumThe Fly
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
25d ago
AZN
BMY
Sanofi announces Executive Committee to support next strategic chapter
PremiumThe Fly
Sanofi announces Executive Committee to support next strategic chapter
25d ago
SNY
Ligand price target raised to $345 from $330 at Craig-Hallum
PremiumThe FlyLigand price target raised to $345 from $330 at Craig-Hallum
26d ago
SNY
LGND
Sanofi Wins FDA Nod for First Anticancer Therapy Delivered via On-Body Injector
Premium
Company Announcements
Sanofi Wins FDA Nod for First Anticancer Therapy Delivered via On-Body Injector
29d ago
6K
SNY
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
Premium
The Fly
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
1M ago
SNY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >